Oncoinvent Announces Promising Interim Results for Radspherin® as a Potential Treatment for Peritoneal Carcinomatoses

Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced an interim data readout of the Phase 1/2a studies of Radspherin® for the treatment of peritoneal carcinomatoses. The studies were closed

Sammanhang: ...The studies were closed for recruitment at the end of 2023, and patients are currently in long-term follow-up. The readout confirmed the previously published results on efficacy and adds further confidence in the ongoing randomized controlled Phase 2 clinical trial for Radspherin® in patients with ovarian cancer....

Omnämnda personer: Peritoneal Carcinomatoses Oncoinvent ASA.

Crunchfish enables secure and scalable mobile card payments

Crunchfish AB (“Crunchfish”) broadens the Digital Cash solution by patenting secure and scalable mobile wallets using Host-based Card Emulation (HCE) for online as well as offline EMV payments leveraging virtual secure elements. This patent-pending application

Sammanhang: ...This patent-pending application is of strategic importance for Crunchfish as it extends the company’s total addressable market and the near-term revenue opportunities considerably as mobile wallets with tokenized HCE payments is the major digital payment method in the world, with almost 5 billion mobile wallets at the end of 2023....

Omnämnda personer: card payments, Card Emulation.